Biotech entity
Sanofi is most often covered alongside FDA, which appears in 3 of these 6 stories. Each story carries 23.7 original sources on average, compared with 3.9 for the broader beat in this window. At 7.2, the average consequence score sits above the same-window beat average of 6.2.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Sanofi is most often covered alongside FDA, which appears in 3 of these 6 stories. Each story carries 23.7 original sources on average, compared with 3.9 for the broader beat in this window. At 7.2, the average consequence score sits above the same-window beat average of 6.2. The negative share is 17%, the same as the 17% benchmark across 556 Biotech stories in the same window. That works out to roughly 0.3 stories per week across a 148-day span. Coverage clusters in fda-approval, which accounts for 3 of those 6, with the remainder spread across 1 other category. We currently track 6 Biotech stories that mention Sanofi, published between February 19, 2026 and July 16, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 556 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sanofi. Shared-story counts are live from our verified record — not editorial picks.
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
Agreement Signed
Landmark FTA officially signed, initiating the ratification process.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
Acoziborole Rollout
The first single-dose oral cure begins deployment, enabling 'screen-and-treat' strategies.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
Strategic Pivot
Talks resume with a new focus on critical minerals and supply chain security.
Talks Stall
Negotiations collapse in Osaka over agricultural quotas and geographic indications.
Negotiations Launched
Formal trade talks begin in Canberra focusing on market access and IP.
Fexinidazole Approval
The first all-oral treatment is approved, requiring 10 days of pills taken with food.
NECT Launch
Nifurtimox-eflornithine combination therapy improves safety but requires complex intravenous administration.
Melarsoprol Introduced
Arsenic-based treatment becomes standard but carries a 5% mortality rate due to toxicity.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
After eight years of complex negotiations, the European Union and Australia have signed a landmark free trade agreement aimed at eliminating regulatory barriers. The deal is set to streamline market access for European biologics while securing critical mineral supply chains essential for advanced medical manufacturing.
The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
The CDC has issued urgent travel advisories for several popular tourist destinations following a confirmed spread of poliovirus. This development signals a significant setback for global eradication efforts and is expected to drive a surge in demand for inactivated poliovirus vaccines (IPV).
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Source: baltimoresun.com · beckershospitalreview.com
Sanofi is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
